CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia-Recent Advances.

ABSTRACT: In order to increase the effectiveness of cancer therapies and extend the long-term survival of patients, more and more often, in addition to standard treatment, oncological patients receive also targeted therapy, i.e., CAR-T cells. These cells express a chimeric receptor (CAR) that specifically binds an antigen present on tumor cells, resulting in tumor cell lysis. The use of CAR-T cells in the therapy of relapsed and refractory B-type acute lymphoblastic leukemia (ALL) resulted in complete remission in many patients, which prompted researchers to conduct tests on the use of CAR-T cells in the treatment of other hematological malignancies, including acute myeloid leukemia (AML). AML is associated with a poorer prognosis compared to ALL due to a higher risk of relapse caused by the develop

SUBMITTER: Zarychta J 

PROVIDER: S-EPMC10252035 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature